Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management

Writing and editing assistance, including preparation of a draft manuscript under the direction and guidance of the authors, incorporating author feedback, and manuscript submission, was provided by Debra Scates, Ph.D., of JK Associates, Inc., and Michael A. Nissen, E.L.S., of AstraZeneca. This support was funded by AstraZeneca.Peer reviewedPublisher PD

Cluster analyses from the real-world NOVELTY study : six clusters across the asthma COPD spectrum

Funding The NOVELTY study is funded by AstraZeneca. ACKNOWLEDGMENTS The authors would like to thank the patients who participated in this study and the NOVELTY Scientific Community and the NOVELTY study investigators who are listed in full in Tables E7 and E8 in the Online Repository. Medical writing support, under the direction of the authors, was provided by Richard Knight, PhD, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med. 2022;175[9]:1298-1304). J. Vestbo is supported by the NIHR Manchester Biomedical Research Centre and the NIHR Manchester Clinical Research FacilityPeer reviewedPublisher PD

Blood Eosinophil Count Predicts Treatment Failure and Hospital Readmission for COPD

ACKNOWLEDGEMENTS This study was funded by AstraZeneca. Editorial support was provided by Joanne M. Faysal, MS, and Jennie G. Jacobson, PhD, CMPP, of JK Associates, Inc., and Michael A. Nissen, ELS, of AstraZeneca. This support was funded by AstraZeneca. DATA-SHARING STATEMENT Data underlying the findings described in this manuscript may be requested in accordance with AstraZeneca’s data-sharing policy described at https://astrazenecagroupdt.pharmacm.com/DT/HomePeer reviewedPublisher PD

CONQUEST Quality Standards : For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care

Acknowledgments We thank Dr Seyi Soremekun, Jonathan Marshall, Jennie Medin and Irena Brookes-Smith for their valuable contributions to the design of the study. We would also like to acknowledge Ms Andrea Teh Xin Yi (BSc, Hons) of the Observational and Pragmatic Research Institute (OPRI), Singapore, for editorial and formatting assistance which supported the development of this publication. Professor Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Funding CONQUEST is conducted by Optimum Patient Care Global and Observational and Pragmatic Research Institute and is co-funded by Optimum Patient Care Global and AstraZenecaPeer reviewedPublisher PD

Heterogeneity within and between physician-diagnosed asthma and/or COPD : NOVELTY cohort

Copyright ©The authors 2021. For reproduction rights and permissions contact [email protected] reviewedPublisher PD

Effectiveness of initiating biologics in severe asthma patients with high steroid exposure

Peer reviewedPostprin

Characterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy

Peer reviewedPostprin

Statins for the primary prevention of cardiovascular events in elderly patients: a picture from clinical practice without strong evidence from clinical trials

Statins have been demonstrated to be beneficial for secondary prevention of cardiovascular (CV) events also in the elderly. However, a great debate is ongoing about the actual effectiveness in the primary prevention in this patient group. Notwithstanding the lack of strong evidence for primary prevention of CV events in the elderly, statins might be prescribed to elderly in general practice, thus contributing to increase the economic burden of this drug type on the Italian National Health System expenditure. We have conducted an analysis using the general practice database of Caserta-1 Local Health Unit. We selected subjects that received at least one statin prescriptions during the years 2004-2005. We stratified statin users according to CV primary and secondary prevention. The data show that 17.3% of statin users are aged 75 and older (median 78). Prevalence of statin use in elderly patients is 10.0%. Primary prevention of CV events represents the most frequent indication of use of statins in this age group (62.7%). In particular, 30.6% of elderly people receiving statins for primary prevention are new users. Almost 40% of statin users aged 75 and older received only one to five statin prescriptions within the study period. Our data show a wide use of statins in patients aged 75 and older, particularly for primary prevention of CV events. These results should be interpreted also in relation to economics. Alternatively the risk of statin-related adverse events increases with age because of polytherapy and reduced hepatic and renal function. Economic impact and a benefit risk ratio assessment of statin therapy for primary prevention of CV events in elderly people should be taken into account